Home › Pharmacology › Phthalylsulfathiazole

Phthalylsulfathiazole

Phthalazolum

For medical students2 min readUpdated 2026-10-10

Phthalylsulfathiazole is an antibacterial drug belonging to the sulfonamide group. Its primary clinical feature is acting exclusively within the intestinal lumen, allowing for the localized suppression of pathogenic microflora without systemic effects on the body.

FormulationsPowder; 0.5 g tablets

Site of ActionIntestinal lumen (local action)

MechanismCleavage of phthalic acid with the release of sulfathiazole

Safety ProfileLow toxicity, systemic side effects are virtually absent

Mechanism of Action: A Classical Prodrug

From a pharmacological standpoint, phthalylsulfathiazole is an inactive prodrug. For the drug to become active, it must undergo biotransformation directly within the gastrointestinal tract.

Upon oral ingestion, the molecule reaches the small intestine where its activation takes place. Phthalic acid is cleaved from the parent compound. This chemical process exposes the amino group, which is critical for the antibacterial activity of all sulfonamides. This cleavage yields the active drug substance — sulfathiazole (also known in pharmacology as norsulfazole). This active metabolite exerts a bacteriostatic effect on microorganisms.

Pharmacokinetics: Why the Drug Acts Only in the Gut

The main pharmacokinetic feature of Phthalazolum (similar to its group analog sulfaguanidine) is its extremely poor absorption from the gastrointestinal tract.

Unlike systemic sulfonamides that are absorbed into the bloodstream, phthalylsulfathiazole remains in the lumen of the GI tract. It does not achieve high concentrations in the blood, bile, or urine. The entire dose is concentrated exclusively in the intestine, establishing a high and stable local therapeutic concentration. This allows for effective bowel sterilization during infectious lesions.

Side Effects and Safety Profile

Due to the lack of significant systemic absorption, the drug has an excellent safety profile and is considered low-toxicity.

Classical adverse effects typical of systemic sulfonamides (such as crystalluria, hematotoxicity, or severe systemic allergic reactions) are practically absent with phthalylsulfathiazole. The drug acts locally and is eliminated naturally with the intestinal contents.

Administration and Prescription Writing

The drug is available as a powder and in 0.5 g tablets. It is administered strictly orally.

Administration Guidelines:

Dosage: 0.5 g per dose.
Frequency: 4–6 times daily. This high frequency is necessary to constantly maintain a high concentration of sulfathiazole in the transient environment of the bowel (as the drug continuously moves through the GI tract).
Timing: 30–40 minutes before meals.

Prescription Example: Students should remember to write the Latin name of the drug in the genitive case.

```latin Rp.: Tab. Phthalazoli 0,5 D.t.d. N. 20 S. Take orally, 1 tablet 4–6 times daily 30–40 minutes before meals. ```

Mnemonic

PHTHALylsulfathiazole: loses PHTHALic acid in the gut to become active sulfathiazole.

Frequently asked questions

What is the molecular mechanism of the bacteriostatic action of sulfathiazole?

The mechanism involves competitive antagonism with para-aminobenzoic acid (PABA) and inhibition of dihydropteroate synthase. In the small intestine, phthalic acid is cleaved from phthalylsulfathiazole, yielding the active substance sulfathiazole. Due to its structural similarity to PABA, it competes with PABA for binding to dihydropteroate synthase. This blocks the synthesis of dihydropteroic acid and prevents the bacterial cell from producing dihydrofolic acid.

What are the main clinical indications for prescribing phthalylsulfathiazole?

Phthalylsulfathiazole is a luminal sulfonamide. It is poorly absorbed from the gastrointestinal tract and creates a high concentration in the intestine. In the small intestine, phthalic acid is cleaved from the drug, releasing the active substance sulfathiazole. The drug is administered 4–6 times daily; it has low toxicity, and adverse effects are practically absent.

With which medications does phthalylsulfathiazole exhibit pharmacodynamic antagonism?

Phthalylsulfathiazole exhibits chemical antagonism with local anesthetics that are derivatives of esters of para-aminobenzoic acid (PABA). These include:

Procaine (novocaine) — upon hydrolysis, releases PABA, which acts as a competitive antagonist to sulfonamides.
Benzocaine (anesthesin) — also releases PABA upon hydrolysis, competing with sulfonamides.

The released PABA neutralizes the antimicrobial action of sulfonamides. Conversely, local anesthetics from other classes (e.g., lidocaine) do not form PABA during metabolism and do not decrease the antimicrobial activity of the drug.

Does phthalylsulfathiazole achieve high concentrations in urine or bile?

No. The drug is poorly absorbed from the GI tract; therefore, it does not enter systemic circulation and does not accumulate in urine or bile. High concentrations are achieved exclusively within the intestinal lumen.

Which sulfonamide has a completely analogous mechanism to phthalylsulfathiazole?

A direct analog in terms of mechanism and localization of action is sulfaguanidine. It also acts exclusively within the intestinal lumen.

Why must the drug be taken so frequently (4–6 times a day)?

Because the drug is unabsorbed and acts locally, it continuously moves through the GI tract and is excreted with feces. Frequent administration is required to maintain a continuous high concentration of the active substance in the intestine.

Go deeper

General mechanism of action of sulfonamides (competitive antagonism with para-aminobenzoic acid).
Comparison of pharmacokinetics between luminal (gut-acting) sulfonamides and systemic agents.
Topical sulfonamides in other fields (e.g., sulfacetamide in ophthalmology).
Indications for luminal antibacterial agents in modern clinical practice.